What goes up must comedown: prevalence rates, characteristics, and coping strategies concerning MDMA aftereffects.
Sean P. Goldy, Kelcy A Klein, David B. Yaden, Sandeep M. Nayak
Psychopharmacology October 17, 2026 DOI: 10.1007/s00213-026-07187-5 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional online survey Peer reviewed |
|---|---|
| Sample size | 497 |
| Population | MDMA-experienced recreational users recruited from Prolific |
| Topics | MDMA |
| Keywords | Aftereffects Mood |
| Key findings | Among 497 MDMA-experienced recreational users, 74.5% reported at least one post-acute negative episode, with onset about 24 hours after ingestion and average duration of 40 hours. Fatigue, difficulty concentrating, restlessness, and headache were most common; 14.6% of those with such episodes reported passive suicidal ideation and 6.2% active suicidal ideation. About 30% used supplements and 5.1% antidepressants as coping strategies, with moderate perceived helpfulness. |
Abstract
MDMA is increasingly being studied for therapeutic applications, yet the prevalence and characteristics of post-acute negative effects remain debated. We aimed to characterize MDMA's post-acute negative effects, including prevalence and symptom profile among recreational users. Given preclinical work and limited human evidence suggesting that certain supplements and antidepressants may mitigate MDMA's negative effects, we also assessed the use of these substances as coping strategies. We conducted a cross-sectional online survey of 497 MDMA-experienced participants recruited from Prolific. The survey assessed post-acute negative effects prevalence, timing, and duration; post-acute side effects; emotional changes, suicidal ideation; and intentional use of supplements or antidepressants to manage symptoms. We compared characteristics of post-acute side effects between MDMA users who self-reported ever experiencing a negative post-acute MDMA experience (colloquially known as a 'comedown') and those who did not. 74.5% of participants reported experiencing a period of post-acute negative effects at least once, with onset occurring approximately 24 hours post-ingestion and lasting an average of 40 hours. The most common symptoms were fatigue (88.1%), difficulty concentrating (85.7%), restlessness (82.9%), and headache (79.7%). 14.6% of post-acute negative effects experiencers endorsed passive suicidal ideation and 6.2% endorsed active suicidal ideation. Regarding coping strategies, 30.3% reported using supplements (most commonly N-acetyl-cysteine, acetyl-L-carnitine, and magnesium) and 5.1% reported using antidepressants, with moderate perceived helpfulness. Post-acute negative effects of MDMA appear prevalent among recreational users in a cross-sectional sample, characterized by fatigue, negative affect, and elevated suicidal ideation. These findings highlight post-acute risks that warrant further investigation.
Comparable studies
Other cross-sectional and survey studies on MDMA, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Recreational MDMA use in Sydney: a profile of ‘Ecstasy’ users and their experiences with the drug Recreational Ecstasy users recruited via snowball peer network | 1992 | Cross-sectional survey | n = 100 |
| Reducedin vivobinding to the serotonin transporter in the cerebral cortex of MDMA (‘ecstasy’) users Male regular ecstasy users and well-matched controls | 1999 | Cross-sectional association study | n = 20 |
| Patterns of simultaneous polysubstance use in drug using university students Drug-using university students | 2006 | Cross-sectional survey | n = 149 |
| Patterns of recreational drug use at dance events in Edinburgh, Scotland Drug users at dance events in Edinburgh, Scotland, UK, aged 16-47, 80% between 18 and... | 2001 | Cross-sectional survey | n = 122 |
| Acute, sub‐acute and long‐term subjective consequences of ‘ecstasy’ (MDMA) consumption in 430 regular users Regular MDMA users | 2003 | Cross-sectional study | n = 466 |
Citations in the library
Cites 24
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of Psychopharmacology July 19, 2010
- Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity Journal of Neuroscience August 1, 1988
- Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. Journal of Pharmacology and Experimental Therapeutics 1987
- 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. The Lancet Psychiatry May 1, 2018
and 19 more in the library